- Home
- TAC vs CRSP Comparison
TAC vs CRSP Comparison
Compare TAC & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAC
- CRSP
- Stock Information
- Founded
- TAC 1909
- CRSP 2013
- Country
- TAC Canada
- CRSP Switzerland
- Employees
- TAC N/A
- CRSP N/A
- Industry
- TAC Electric Utilities: Central
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TAC Utilities
- CRSP Health Care
- Exchange
- TAC Nasdaq
- CRSP Nasdaq
- Market Cap
- TAC 3.1B
- CRSP 3.5B
- IPO Year
- TAC N/A
- CRSP 2016
- Fundamental
- Price
- TAC $13.85
- CRSP $40.48
- Analyst Decision
- TAC
- CRSP Buy
- Analyst Count
- TAC 0
- CRSP 18
- Target Price
- TAC N/A
- CRSP $76.60
- AVG Volume (30 Days)
- TAC 1.4M
- CRSP 1.9M
- Earning Date
- TAC 11-05-2024
- CRSP 11-05-2024
- Dividend Yield
- TAC 1.24%
- CRSP N/A
- EPS Growth
- TAC N/A
- CRSP N/A
- EPS
- TAC 0.38
- CRSP N/A
- Revenue
- TAC $2,065,953,587.00
- CRSP $202,829,000.00
- Revenue This Year
- TAC N/A
- CRSP N/A
- Revenue Next Year
- TAC N/A
- CRSP $758.18
- P/E Ratio
- TAC $35.31
- CRSP N/A
- Revenue Growth
- TAC N/A
- CRSP 19.31
- 52 Week Low
- TAC $5.94
- CRSP $39.41
- 52 Week High
- TAC $14.64
- CRSP $91.10
- Technical
- Relative Strength Index (RSI)
- TAC 72.02
- CRSP 31.88
- Support Level
- TAC $13.68
- CRSP $42.86
- Resistance Level
- TAC $14.64
- CRSP $44.99
- Average True Range (ATR)
- TAC 0.62
- CRSP 2.39
- MACD
- TAC 0.09
- CRSP -1.11
- Stochastic Oscillator
- TAC 75.62
- CRSP 2.58
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, hydro, wind & solar, Energy Marketing, gas, energy transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.